Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.63 |
| ▸ | GSPT1 | P15170 | 8/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795962 | 1.00 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240044 | 0.91 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23213483 | 0.91 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240227 | 0.91 | CRBN (0.63) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240032 | 0.91 | CRBN (0.64) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23239950 | 0.91 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240029 | 0.91 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240224 | 0.90 | CRBN (0.64) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL24782465 | 0.89 | CRBN (0.60) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240056 | 0.88 | CRBN (0.62) | CRBNGSPT1DDB1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CRBN 524/4885GSPT1 1795/4885DDB1 2502/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | CRBN 671/4885GSPT1 4622/4885DDB1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.